You are here

Article Text

Article menu
Download PDFPDF
Harms
Systematic review and meta-analysis
Risk of venous thrombosis varies with different types of combined oral contraceptives
  1. Maria T DeSancho
  1. Department of Medicine, Weill Cornell Medical Center, New York, New York, USA
  1. Correspondence to : Dr Maria T DeSancho, Department of Medicine, Weill Cornell Medical Center, 1305 York Avenue, 7th Floor, New York, NY 10021. USA; mtd2002{at}med.cornell.edu

https://doi.org/10.1136/eb-2013-101605

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Stegeman BH, de Bastos M, Rosendaal FR, et al. Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis. BMJ 2013;347:f5298.OpenUrlAbstract/FREE Full Text

    Context

    Combined oral contraceptives (COC) are associated with a twofold to sixfold increased risk of venous thrombosis (VT).1 Risk is highest during the first year of use, but persists until discontinuation. Although the incidence of VT is low in women of reproductive age (approximately 3/10 000 woman-years), the effect of COC in VT is significant because many women use them. All COC increase the risk of VT, but those containing third-generation progestogens (desogestrel and gestodene) augment the VT risk approximately twofold compared to oral contraceptives containing second-generation progestogens (levonorgestrel and norgestrel). The risk of VT with drugs containing cyproterone and drospirenone is similar …

    View Full Text

    Footnotes

    • Competing interests None.